A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Clinical trial NCT02896855 · COMPLETED
Trial details
- NCT number
- NCT02896855
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-13
- Primary completion
- 2018-06-27
- Enrollment
- 243
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.